Annales pharmaceutiques francaises最新文献

{"title":"An investigative review for pharmaceutical analysis of angiotensin receptor blockers: Olmesartan medoxomil.","authors":"Vinod Ambalal Chaure, Atul Arun Shirkhedkar","doi":"10.1016/j.pharma.2024.10.001","DOIUrl":"10.1016/j.pharma.2024.10.001","url":null,"abstract":"<p><p>Hypertension is often asymptomatic and can substantially elevate the risk of cardiovascular complications. Olmesartan medoxomil works by competitively blocking the angiotensin II receptors, preventing angiotensin II from constructing the blood vessels and releasing aldosterone. This discussion is focused on the critical analytical methods used to analyze olmesartan medoxomil in pharmaceutical and biological samples. A variety of analytical methods have been employed to both qualitatively and quantitatively determine the analyte, including high-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC), voltammetry, capillary zone electrophoresis, UV/Vis spectrophotometry, and 96-microwell assays. The review also includes official methods published in the Indian Pharmacopoeia. Based on existing literature, simple spectrophotometry and liquid chromatography are commonly used to analyze olmesartan medoxomil. These findings provide a solid foundation for future olmesartan medoxomil drug analysis research.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-malarial evaluation of selected medicinal plants traditionally used for treatment of fever, by inhibition test of heme polymerization.","authors":"Arian Salimi, Maryam Hamzeloo-Moghaddam, Mahboobeh Irani, Somayeh Esmaeili","doi":"10.1016/j.pharma.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.10.003","url":null,"abstract":"<p><strong>Objectives: </strong>World Health Organization (WHO) has reported 249 million cases infected by malaria worldwide and 608 thousands deaths in 2022. Investigations for new antimalarial drugs from traditional medicine have proven to be more effective and less expensive. The medicinal plants that have been used for treatment of malaria, generally known as types of fevers in traditional medicine, can be suitable candidates for evaluating antimalarial effects. The aim of the present study was to evaluate the in-vitro mechanism of antimalarial action of selected medicinal plants by inhibition test of heme detoxification (ITHD).</p><p><strong>Material and methods: </strong>The methanol extract and fractions were prepared through maceration of the dry powdered plants. The ITHD method was carried in 96-wells plate and the percentage of heme polymerization inhibition was determined. The cytotoxicity of the effective plants were examined on MDBK cell line by MTT assay. Bioassay guided fractionation was performed exposing to size exclusion column chromatography and liquid-liquid fractionation and was assayed by the ITHD method for the sample with the least IC₅₀ value and lowest cytotoxic effect.</p><p><strong>Results: </strong>The methanol fraction of Viola odorata whole plant showed the most considerable results among the tested plants with IC₅₀ 171.8 μg.mL^-1 beside the lowest cytotoxic effects. This fraction by the bioassay guided fractionation led to fraction SB₂ and this fraction demonstrated the most effective result with lowest IC₅₀ = 14.8 ± 3µg.mL^-1 in ITHD assay.</p><p><strong>Conclusion: </strong>Regarding the results of the present study and the traditional use of V. odorata for overcoming fever in Iranian traditional medicine, the final fraction of the plant could be proper candidate for further phytochemical and antimalarial studies.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Epigenetic changes in alcohol addiction and therapeutic perspectives].","authors":"Olivier Pierrefiche","doi":"10.1016/j.pharma.2024.09.009","DOIUrl":"10.1016/j.pharma.2024.09.009","url":null,"abstract":"<p><p>Alcohol consumption is a major public health issue. Patients with Alcohol Use Disorder (AUD) can benefit from five treatments that preferentially target membrane receptors, and whose efficacy is generally modest. However, a large body of experimental evidence points to an important role for epigenetics in the effects of alcohol consumption, and epidrugs that modify the epigenome offer an interesting alternative to current therapeutic options. This article reviews the most striking experimental evidence obtained at different ages in animal models, before comparing it with data obtained in humans and concluding on the relevance of using epidrugs. Finally, a new therapeutic option is suggested between psychedelics, recent molecules of interest, and epigenetic factors in alcohol intake.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Risk analysis applied to the monitoring of immunosuppressor concentrations in lung transplant recipients].","authors":"Agathe Landoas, Romane Chapuis, Amandine Briault, Quentin Perrier, Pierrick Bedouch","doi":"10.1016/j.pharma.2024.09.010","DOIUrl":"10.1016/j.pharma.2024.09.010","url":null,"abstract":"<p><p>Mastering and monitoring immunosuppressant concentrations is central to the care of lung transplant patients and involves multiple stakeholders. The objective is to conduct a risk analysis to evaluate the impact of various actions taken. The lung transplantation team was convened to carry out a failure mode effect analysis. The process was divided into stages where different risks were identified. The risk priority number (RPN) (severity, frequency, detectability) and risk level of criticality (frequency, severity) were established before implementation of actions (before 2009) and then after (in 2022) to classify risks according to four levels of criticality. The implemented actions included the establishment of a quality assurance process, computerization of monitoring, and double analysis by a physician/pharmacist pair. Thirty-two risks were identified during the four stages of the process: biological sampling (n=13), reception (n=3), analysis and treatment of levels (n=5), transmission of information/prescriptions to the patient (n=11). The total raw RPN (before 2009) was 839, with 12 major risks. The current total RPN (in 2022) was 452 (a decrease of 46.1%), with 7 major risks identified. The analysis enabled the objective evaluation of the effectiveness of the actions taken. The most secure stage of the process is the reception of residual level results. Efforts should focus on empowering and involving patients, as well as engaging local stakeholders in collaboration with the specialized transplantation team.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review on novel pharmaceutical applications of hupu gum: A versatile natural polymer.","authors":"Rajeswari Aleti, Monika Nijhawan, Pavan Kumar Thota, Bhavana Jidige","doi":"10.1016/j.pharma.2024.09.008","DOIUrl":"10.1016/j.pharma.2024.09.008","url":null,"abstract":"<p><p>The pharmaceutical research on natural excipients with diverse physicochemical properties useful in various novel drug delivery systems is a growing interest. The market for natural gums like hupu gum (gum kondagogu) is growing globally, driven by increasing consumer preference for natural and sustainable ingredients. This review covers botanical origin, geographical distribution, chemical constituents, identification tests, toxicology studies and potential applications of hupu gum in novel drug delivery systems. Emphasis is placed on its traditional uses in indigenous medicine and current research findings and patents that highlight its emulsifying, stabilizing, film forming, and thickening properties. Hupu gum is a tree exudate from Cochlospermum religiosum belonging to the family Bixaceae. It is traditionally used for various medicinal and industrial purposes as it has a unique chemical composition and physical properties. Moreover, the current research and use of hupu gum as a biopolymer in the formulation and stabilization of nanoparticles (NP) is expanding the application spectrum of hupu gum. This writeup typically conclude with insights into future research directions, such as, exploring new applications, or enhancing its functional properties through modification.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of the toxicity of the essential oil of Brocchia cinerea.","authors":"Mohammed Tahar Ben Moussa, Said Nadji, Nawel Achachi, Safa Chaira, Rafika Laiche, Soumaya Boudjemaa, Abdelhakim Bounab, Hassina Harkat, Youcef Hadef","doi":"10.1016/j.pharma.2024.09.007","DOIUrl":"10.1016/j.pharma.2024.09.007","url":null,"abstract":"<p><p>Brocchia cinerea is a North African plant belonging to the Asteraceae family, widely utilized in Algerian folk medicine to treat a variety of illnesses. These therapeutic virtues are mainly due to the plant essential oil. The chemical components of this oil were identified using GC-MS, and the variability in these components' levels was examined in nine samples that were taken at different times from two locations in Algeria's northern Sahara. The contents of the essential oil were found to consist of eight components, varying in concentrations: beta-thujone (46.80%), 1-Methyl-2-(1' methylethenyl) -3'- ethenylcyclopropylmethanol (14.59%), 1,8-Cineole (12.63%), limonen-10-ol (9.47%), 1(7),3,8 o Menthatriene (3.45%), and (-)-Camphor (2.11%). Toxicity studies were conducted in order to assess the safety of the essential oil, namely: LD50 estimation and biochemical blood parameters evaluation. The results showed an LD 50 of 507.5mg/kg close to the LD50 of Beta-thujone (442mg/kg): the main component of the essential oil, making it accountable for the major toxicity. The apparition of seizures as toxic manifestations for higher concentrations confirmed that. The essential oil of Brocchia was noted to be classified as slightly, weakly toxic, and the Beta-thujone contents showed to be within the regulatory accepted values, which makes the use of Brocchia safe within the indicated standards.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Construction of a methodology for clinical evaluation of medical devices using simulation tools and illustration through three studies].","authors":"Cordélia Salomez-Ihl, Claire Chapuis, Pierre Albaladejo, Marielle Picard, Aline Baron, Paz Pardo Garcia, Jean-Noël Evain, Joris Giai, Maud Barbado, Alexandre Moreau-Gaudry, Jean-Luc Bosson, Julien Picard, Pierrick Bedouch","doi":"10.1016/j.pharma.2024.09.003","DOIUrl":"10.1016/j.pharma.2024.09.003","url":null,"abstract":"<p><strong>Introduction: </strong>European regulations have recently moved towards more stringent requirements for demonstrating the safety and performance of medical devices (MDs).</p><p><strong>Objective: </strong>To apply an innovative testing method using medical simulation to the evaluation of three medical devices at different stages of their life cycle.</p><p><strong>Method: </strong>The methodology for evaluating DMs using simulation is based on seven stages: definition of the context, training, construction of a scenario to test the DM, validation of the scenario, realization of the scenario, evaluation of the scenario by the players and validation and exploitation of the results.</p><p><strong>Results: </strong>Our evaluation methodology enabled us to assess three DMs at different stages of their development: a respiratory protection device at the initial stage (prototype definition), a respiratory protection mask (prototype optimization) and bottle adapters (post-marketing).</p><p><strong>Conclusion: </strong>Simulation is a valuable tool for evaluating DM. The proposed methodology enables it to be used and adapted to different contexts. It responds to the specificities of clinical evaluation of this class of products, and helps to better anticipate certain risks.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing antibiotic prescribing practices at the main military training hospital of Tunis: A study of pharmaceutical interventions.","authors":"Aloui Ghaith, Sana Bennour, Yousfi Mohamed Ali","doi":"10.1016/j.pharma.2024.09.006","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.09.006","url":null,"abstract":"<p><strong>Background: </strong>Bacterial infections have historically posed significant challenges until the discovery of antibiotics, which revolutionized infectious disease treatment. However, bacterial adaptation mechanisms over time have led to increased antimicrobial resistance, necessitating judicious antibiotic use.</p><p><strong>Objectives: </strong>This study aims to comprehensively analyze pharmaceutical interventions related to antibiotic prescriptions governed by antibiotic order forms to identify and rectify medication errors, optimizing antibiotic prescribing practices.</p><p><strong>Material and methods: </strong>Approval for this research was obtained from the institutional review board of the Main Military Training Hospital of Tunis, Tunisia. A retrospective study was conducted at the main military training hospital of Tunis over 4 months. Pharmaceutical validation of antibiotic prescriptions through antibiotic order forms was conducted by a pharmacy resident. Pharmaceutical interventions were initiated upon detection of errors, and patient records were accessed through institutional software.</p><p><strong>Results: </strong>Out of 1100 prescription forms analyzed, 41 pharmaceutical interventions were conducted for 7 antibiotics. Twenty-four percent of all interventions were related to antibiotic order forms, with the intensive care unit accounting for the highest number of errors. Under-dosage and prescription errors were common.</p><p><strong>Conclusion: </strong>Our pharmaceutical interventions related to antibiotic order forms are crucial for optimizing antibiotic therapy. Feedback mechanisms to healthcare teams are essential for enhancing prescription quality and patient care outcomes. Ongoing surveillance and improvement efforts are necessary to address medication errors and enhance antimicrobial stewardship.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo pharmacokinetic study of carmustine in rats after giving single-dose of carmustine API solution, flexible liposomes, in situ nasal gel, optimized flexible liposomes embedded in situ nasal gel, and marketed formulation.","authors":"Audumbar Mali, Anil Bhanwase","doi":"10.1016/j.pharma.2024.09.002","DOIUrl":"10.1016/j.pharma.2024.09.002","url":null,"abstract":"<p><strong>Background: </strong>Carmustine is used in the treatment of glioblastoma (GBM). GBM is a well-known life-threatening type of cancerous tumor. GBM covers 60.00% among all primary brain tumors, with an occurrence of 74,000 cases across the globe. Management for GBM is still very difficult because most of the medicines are unable to cross the blood-brain barrier (BBB). The present work observed that flexible liposomes embedded in situ nasal gel of carmustine is the best brain-targeted medicine delivery system for the management of GBM through the nasal route.</p><p><strong>Aim: </strong>To evaluate in vivo pharmacokinetic parameters of carmustine formulations administered through nasal routes in Wistar rats.</p><p><strong>Methods: </strong>In this work, different pharmacokinetic parameters were determined for carmustine formulations viz. carmustine API (Active Pharmaceutical Ingredient) solution, flexible liposomes, in situ thermoreversible intranasal gel, optimized flexible liposomes embedded in situ thermoreversible intranasal gel via intranasal administration in rats, and compared with marketed intravenous injection of carmustine administered through intravenous route. Carmustine was estimated with the help of a validated high-performance liquid chromatography (HPLC) approach. Three to four-months-old normal Wistar rats of either sex, having a weight of 200-250 grams were used in this study.</p><p><strong>Results: </strong>Intranasal administration of optimized flexible liposomes embedded in situ nasal gel showed greater C_max (∼two-fold), AUC_0→t (∼three-fold), AUC_0→∞ (∼six-fold), and decreased T_max (1h) data in the brain, than commercial intravenous injection of carmustine. The plasma concentration of carmustine administered through nasal route was found to be comparatively lower than intravenous administration, indicating lower systemic exposure to carmustine via the nasal route.</p><p><strong>Conclusion: </strong>In vivo pharmacokinetics results revealed that the optimized flexible liposomes embedded in situ nasal gel of carmustine can effectively deliver carmustine to brain by nasal drug delivery system in Wistar rats.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and characterization of palbociclib-loaded PLGA nanobubbles for targeted cancer therapy.","authors":"Boddu Kishore Kumar, Gubbiyappa Shiva Kumar","doi":"10.1016/j.pharma.2024.09.005","DOIUrl":"https://doi.org/10.1016/j.pharma.2024.09.005","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to develop and optimize palbociclib-loaded nanobubbles for targeted breast cancer therapy.</p><p><strong>Materials and methods: </strong>Biocompatible poly(DL-lactide-co-glycolide) was used to create nanobubbles loaded with palbociclib. The formulation process was meticulously crafted using a three-level Box-Behnken design and a double emulsion solvent evaporation method to precisely tailor the nanobubbles' properties.</p><p><strong>Results: </strong>The Derringer's desirability method optimized variables by transforming responses into a desirability scale, resulting in a global desirability value. Optimal settings, A: 526.97mg, B: 250mg,C: 2.0% w/v, D: 6101rpm, achieved a D value of 0.949. Palbociclib nanobubbles demonstrated a smaller particle size (31.78±2.12) than plain nanobubbles (38.56±3.56). PDI values indicated a uniform size distribution. The zeta potential remained consistent, with values of -31.34±3.36 for plain and -31.56±3.12 for drug-loaded nanobubbles. Encapsulation efficiency was 70.12%, highlighting effective drug encapsulation. Palbociclib release was significantly higher from nanobubbles in pH 7.4, especially with ultrasound, releasing almost 99.34% of the drug. Hemolytic activity assays confirmed safety for injection. Fluorescent intensity analysis revealed a two-fold increase in cellular uptake of palbociclib facilitated by ultrasound. The MTT assay demonstrated enhanced cytotoxicity of palbociclib-loaded nanobubbles, especially with ultrasound, emphasizing their potential for improved therapeutic efficacy. The IC₅₀ values for palbociclib, without ultrasound, and with ultrasound were 98.3μM, 72.34μM, and 61.34μM, respectively.</p><p><strong>Conclusion: </strong>The significant findings of this study emphasize the potential of palbociclib-loaded nanobubbles as a promising therapeutic system for improved breast cancer treatment.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}